Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.
|
31831854 |
2020 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL leukemias result from leukemic stem cell/progenitor transformation and represent an opportunity to identify epigenetic progress contributing to lineage leukemogenesis.
|
30610188 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCR-ABL1 oncogene is associated with chronic myeloid leukemia (CML) pathogenesis, but the molecular mechanisms that initiate leukemogenesis are still unclear.
|
30738963 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As mutations in STAT5B, but not STAT5A, have been frequently described in hematopoietic tumors, we used BCR/ABL as model systems to investigate the contribution of STAT5A or STAT5B for leukemogenesis.
|
30679796 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The bcr-abl fusion gene encodes BCR-ABL oncoprotein and plays a crucial role in the leukemogenesis of chronic myeloid leukemia (CML).
|
31138265 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that BCR-ABL is localized to stress granules and that its granular localization contributes to BCR-ABL-dependent leukemogenesis.
|
31735741 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms.
|
29288910 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
|
28819285 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nevertheless, functional studies would be needed to establish the biological role of AIF1L-ETV6 and ABL1-AIF1L and to determine whether they contribute to leukemogenesis and/or to the final leukemia phenotype.
|
29726059 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Depending on the translocation breakpoint, typically a p210 BCR-ABL1 or a p190 BCR-ABL onc protein are generated; both are constitutively active tyrosine kinases that play a central role to alter signaling pathways of cell proliferation, survival, and self-renewal, leading to leukemogenesis.
|
28971501 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that genomic depletion of miR-17-92 inhibited the BCR-ABL induced leukemogenesis by using a mouse model of transplantation of BCR-ABL transduced hematopoietic stem cells.
|
28461114 |
2017 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that BCR-ABL activates BLT2 in hematopoietic stem/progenitor cells to promote leukemogenesis and this involves the p53 signaling pathway.
|
26966074 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis.We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation.
|
27821800 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, its function in BCR-ABL-mediated leukemogenesis in vivo is still unknown.
|
25249015 |
2015 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data suggest that BTG1 deletions might play a role in leukemogenesis of BCP-ALL as well as of BCR-ABL1-positive MPAL and CML-BC (B-lineage).
|
24998463 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, its substrates have been found to be essential for p210BCR-ABL1 leukemogenesis or CML progression.
|
24647617 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
|
23208504 |
2014 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
|
23894305 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chimeric oncogene BCR/ABL, which is the product of reciprocal translocation between chromosomes 9 and 22, is a known molecular marker of chronic myeloid leukemia (CML), and is related to the major factors involved in leukemogenesis.
|
24301757 |
2013 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altered expression of the anti-apoptoticBcl-xL has been correlated with BCR-ABL leukemogenesis; however, its involvement in the pathogenesis and evolution of CML has not been formally demonstrated yet.
|
23670294 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of β-catenin was linked to CML leukemogenesis and drug resistance through its BCR-ABL-dependent Y phosphorylation and impaired binding to GSK3β (glycogen synthase kinase 3β).
|
22262776 |
2012 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that SIRT1 is a novel survival pathway activated by BCR-ABL expression in hematopoietic progenitor cells, which promotes oncogenic transformation and leukemogenesis.
|
22207735 |
2012 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together these data demonstrate a critical role for autophagy to mitigate cell stress, and that cells expressing the oncogenic kinase BCR-Abl appear particularly dependent on autophagy for cell survival and leukemogenesis.
|
21151168 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid leukemia (CML), characterized by the t(9;22) and BCR/ABL1 fusion, is a disease model for studying the mechanisms of genetic abnormalities in leukemogenesis.
|
22118744 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that FANCD2-Ub has an important role in BCR-ABL1 leukemogenesis because of its ability to facilitate the repair of numerous ROS-induced DSBs.
|
21519342 |
2011 |